Home › Entities › clinical_trial › Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults

clinical trial
MedicalStudy clinical_trial Q93328984
Press Enter · cited answer in seconds

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults

Summary

Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults is a clinical trial[1].

Key Facts

  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults is in the country of United States[2].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults is in the country of Argentina[3].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults is in the country of Brazil[4].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's instance of is recorded as clinical trial[5].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's start time is recorded as +2020-04-28T00:00:00Z[6].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's end time is recorded as +2023-01-27T00:00:00Z[7].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's contributor to the creative work or subject is recorded as Pfizer[8].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's main subject is recorded as Pfizer–BioNTech COVID-19 vaccine[9].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's main subject is recorded as RNA vaccine[10].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's main subject is recorded as COVID-19[11].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's number of participants is recorded as {'unit': '1', 'amount': '+29481'}[12].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's title is recorded as A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-COV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults[13].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[14].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's ClinicalTrials.gov ID is recorded as NCT04368728[15].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+85'}[16].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's research intervention is recorded as Pfizer–BioNTech COVID-19 vaccine[17].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's clinical trial phase is recorded as phase I clinical trial[18].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's clinical trial phase is recorded as phase II clinical trial[19].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's clinical trial phase is recorded as phase III clinical trial[20].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's research subject recruitment status is recorded as recruiting[21].
  • Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults's study type is recorded as interventional study[22].

References

Programmatic citations — every numbered marker resolves to a verifiable graph row below.

Direct Wikidata claims

  1. [2] ↑ . wikidata.org.
  2. [3] ↑ . wikidata.org.
  3. [4] ↑ . wikidata.org.
  4. [5] ↑ . wikidata.org.
  5. [6] ↑ . wikidata.org.
  6. [7] ↑ . wikidata.org.
  7. [8] ↑ . wikidata.org.
  8. [9] ↑ . covid-19tracker.milkeninstitute.org. Retrieved . covid-19tracker.milkeninstitute.org. Provenance: wikidata.org.
  9. [10] ↑ . wikidata.org.
  10. [11] ↑ . wikidata.org.
  11. [12] ↑ . wikidata.org.
  12. [13] ↑ . wikidata.org.
  13. [14] ↑ . wikidata.org.
  14. [15] ↑ . wikidata.org.
  15. [16] ↑ . wikidata.org.
  16. [17] ↑ . covid-19tracker.milkeninstitute.org. Retrieved . covid-19tracker.milkeninstitute.org. Provenance: wikidata.org.
  17. [18] ↑ . wikidata.org.
  18. [19] ↑ . wikidata.org.
  19. [20] ↑ . wikidata.org.
  20. [21] ↑ . wikidata.org.
  21. [22] ↑ . wikidata.org.

Class ancestry

  1. [1] ↑ . Wikidata. wikidata.org.

📑 Cite this page

Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.

APA 4ort.xyz Knowledge Graph. (2026). Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults. Retrieved May 3, 2026, from https://4ort.xyz/entity/study-to-describe-the-safety-tolerability-immunogenicity-and-potential-efficacy-of-rna-vaccine-candidates-against-covid-19-in-healthy-adults
MLA “Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults.” 4ort.xyz Knowledge Graph, 4ort.xyz, 3 May. 2026, https://4ort.xyz/entity/study-to-describe-the-safety-tolerability-immunogenicity-and-potential-efficacy-of-rna-vaccine-candidates-against-covid-19-in-healthy-adults.
BibTeX @misc{4ortxyz_study-to-describe-the-safety-tolerability-immunogenicity-and-potential-efficacy-of-rna-vaccine-candidates-against-covid-19-in-healthy-adults_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults}}, year = {2026}, url = {https://4ort.xyz/entity/study-to-describe-the-safety-tolerability-immunogenicity-and-potential-efficacy-of-rna-vaccine-candidates-against-covid-19-in-healthy-adults}, note = {Accessed: 2026-05-03}}
LLM prompt According to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults — https://4ort.xyz/entity/study-to-describe-the-safety-tolerability-immunogenicity-and-potential-efficacy-of-rna-vaccine-candidates-against-covid-19-in-healthy-adults (retrieved 2026-05-03)

Canonical URL: https://4ort.xyz/entity/study-to-describe-the-safety-tolerability-immunogenicity-and-potential-efficacy-of-rna-vaccine-candidates-against-covid-19-in-healthy-adults · Last refreshed: